Sanofi Showcases Multiple Innovative Products at 2023 Zhongguancun Forum Exhibition

Deepen Local Investment, Share a Healthy Future

BeijingMay 26, 2023PR Newswire -- Today, Sanofi, a global leading innovative pharmaceuticals and healthcare company, participated in the 2023 Zhongguancun Forum Exhibition (China Science and Technology Fair), showcasing multiple strategic innovative products across all therapeutic areas including chronic diseases, immunology and inflammation, rare diseases, vaccines, and consumer healthcare. Making its debut at the Zhongguancun Forum Exhibition, Sanofi will comprehensively present world-leading innovations, demonstrating its commitment to deepening development in Beijing and across China, as well as its long-term dedication to supporting the Healthy China initiative.

Wang Shi, President of Sanofi Greater China"Over the years of our deep development in Beijing, we have truly felt how the Beijing government has continuously created an open and convenient investment environment for foreign enterprises through open policies and innovation-encouraging measures. This has injected confidence and strength into our construction and development in Beijing. In the future, Sanofi will firmly commit to its investment and construction in Beijing and its long-term commitment in China, introducing more innovative pharmaceuticals and healthcare products and services to benefit the people of China."

The 2023 Zhongguancun Forum officially opened in Beijing on May 25. It is an international forum with national, cutting-edge, and international characteristics and serves as a platform for top leaders in various fields to showcase significant achievements and exchange forward-thinking ideas. The 2023 Zhongguancun Forum Exhibition (China Hi-Tech Fair), as the exhibition section, themed "Open Cooperation, Shared Future," invited numerous experts and entrepreneur representatives from various industries. Its aim is to provide more opportunities for international scientific and technological exchanges and cooperation for industry-leading companies, including Sanofi.

Innovation Showcase: Debut Exhibition of Pharmaceutical and Health Achievements Shines

At this year's Science and Technology Expo, Sanofi showcased nearly 20 innovative products:4Chronic Disease Field Products, including the innovative compound formulation Soliqua® in the diabetes field that was approved for marketing in early 2023, and the long-acting basal insulin Toujeo.^®; Revolutionary Innovation in Cardiovascular Field: The Lipid-Lowering Drug Polid^®And the innovative drug Zenon* for potent lipid management.4Products in the field of immune inflammation and rare diseases, including Dupixent, which expands the new indication for moderate to severe atopic dermatitis to the infant and toddler population.^®* (The only systemic treatment drug for atopic dermatitis that covers the entire population), Sarclisa, a novel CD38 monoclonal antibody drug for the treatment of adult multiple myeloma.^®*、The first enzyme replacement therapy drug for Fabry disease approved by the FDA in China, Fabrazyme.^®`, as well as the new generation enzyme replacement therapy drug Nexviazyme for Pompe disease`^®*。

InInnovative VaccinesAspect, the products exhibited this time are Beyfortus* and Valganciclovir.^®Two products. Beyfortus is the world’s first and only long-acting monoclonal antibody for RSV prevention that can be widely used in infants; quadrivalent influenza virus split vaccine Familiaria.^®Universal Indication for All Age Groups (6 months and above) was approved for marketing in China this May, providing a new option for influenza vaccines with a unified formulation for the entire population. Additionally, there are9Consumer Healthcare ProductsAlso debuted at this year's Science and Technology Expo, with the OTC liver protection product Essentiale.^®Four prescription and over-the-counter drugs represented by Sanofi, and five cross-border health and personal care products represented by Ostelin Children's Milk Calcium Chewable Tablets.

Sanofi Exhibits at the 2023 Zhongguancun Forum Exhibition

Spanning Four Decades, Upholding Commitment to Investment in Beijing and China

As one of the first multinational pharmaceutical companies to enter China after the reform and opening up, Sanofi has been deeply rooted in the Chinese market for over 40 years. In China, a key market in Sanofi's global strategy, Sanofi has introduced more than 40 drugs to the Chinese people in the fields of chronic diseases, specialty medicines, vaccines, and consumer healthcare. It continues to accelerate the introduction of innovative drugs and vaccines into China to meet diverse health needs.

Beijing boasts a world-class business environment characterized by marketization, rule of law, and internationalization, along with diverse institutional innovations, making it an ideal location for multinational companies to develop in China. This has attracted Sanofi to establish its presence in Beijing. In 1995, Sanofi's Beijing production base officially settled in the Beijing Economic and Technological Development Zone, producing over 20 products covering areas such as diabetes, cardiovascular health, internal medicine, and oncology. After years of strategic development, Beijing’s economic development zone has formed a complete biopharmaceutical industry chain, continuously promoting a new development pattern of high-level opening up. In 2022, seizing the opportunity presented by Beijing's "Two Zones" initiative, Sanofi planned to invest nearly 500 million yuan to expand its insulin production capacity at the Beijing production base, aiming to better meet the treatment needs of Chinese diabetes patients. The rapid development of Sanofi’s Beijing production base has made it the largest insulin production site in the Asia-Pacific region for Sanofi, delivering significant innovative achievements to both the Chinese and global markets.

Committed to the Chinese market, Sanofi will continue to deepen its localization exploration and practice, accelerate innovation, and provide Chinese patients with more high-quality and sustainable medical solutions, contributing to the vigorous development of China's health care industry as a "localized multinational pharmaceutical company."

* The Product/Indications have not yet been approved for marketing in China, limited to2023Zhongguan Village Forum Exhibition (Science and Technology Expo) Display Use

* Dupixent® 6Months of age to5The indication for moderate to severe atopic dermatitis in children has not been approved in China.